Member Info for stephen11

Latest screen is showing all buys - this could change to blue again today (stranger things have happened on AIM).

It's great that senior employees are being incentivised, however I would have liked to see the finer details. The RNS reads:

"The Options have been granted with an exercise price of 12.25p being equal to the closing price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending 30 June 2025. The Options are exercisable over the period of 10 years from the date of grant."

What are the certain performance criteria that must be met?
What is the revenue target?
What is the cash target?
What strategic projects must be completed by year-ending 30th June 2025?

Other AIM listed stocks are much more transparent about incentive programmes (e.g., Kodal Minerals - no cross ramp intended). I feel like, on this occasion GDR have given us half the story!

GLA.

GLA.

Showing 37.5% on HL.

Only the start though.

GLA.

Will be great to get extra exposure in the European market.

Exactly the point i'm making Pollywold. If 5.1m of the fundraise is to be used on existing projects, then the answer to my question at the investormeet could be described as inaccurate, at best.

I think this is a great company, but after 30 years of investing, i like to call a spade a spade.

They would have known this at the meeting and still said no fund raises would take place - watch the meeting again and you can see for yourself.

At the Investormeetcompany presentation!

Am i missing something!

The board said they were financed through to the second half of next year. I know this as i asked a question about cash burn and when a fundraise was needed.

This is only the beginning for this stock.

I’m happy my shares are safely tucked away for couple of years in my tax free isa.

GLA.

Was the 28th 0ct 2021 and the subsequent investormeetcompany presentation was the 9th November 2021, so hopefully not long now until we know when the final results will be announced.

GLA.

Everyone’s patience will be rewarded.

Looks like the tea lady has been talking.

GLA

I hope so. If this gets to 200p i'd be OUT quicker than Kwasi Kwarteng!

GLA.

Some like this share and are accumulating blocks of 100,000 shares anyways if you look at the trades.

Fair points Stares and Popeye and thanks for sharing.

I look forward to seeing the minutia from the company at the next investormeetcompany event.

GLA.

Or? Do all of the items below cost £60? i.e., 1 case of supplies?

Product Code Product Description Pack Quantity
GS-002 Genedrive System 1 unit
ID-RNR1-01 Genedrive MT-RNR1 ID Kit 1 box (10 Kits)
RNR1-CTRL-01 Genedrive MT-RNR1 Control Kit 1 box (4 Kits)
GS-002-PTR Genedrive Star label printer with
charging cradle 1
GDS-187 Replacement Printer Labels 20 rolls

If this is the case, then it would be 2792 x £60 = £167,520

I don't know, i'm confused!

Fair point mcco,

Always inspires a bit of market confidence when a board buys in and puts some skin in the game!

GLA.

This is a great find starresnstoff!

Does it definitely say 10 pouches per kit? If this just for the North-West of England these figures are very exciting, especially when this is extrapolated to the UK.

27920 @ £60 each = £1.765 million (finally a bit of light at the end of the tunnel). I wonder what the profit margin is per test! I can't recall this info being previously cascaded. Does anyone know?

Put America into the equation next year and the sky is the limit.

It is estimated that one in every one hundred children worldwide have ASD (1% of the child population). The market is massive and there are currently no other approved treatments.

GLA.

Licensing Deal with Stalicla and Clinical Progress Update

* The company had 9m in cash reserves as of 31 March 2022
* Therefore, the company has a cash runway to at least Q4 2022; and indeed, well into 2025 if Stalicla milestones are included
* There is currently no approved treatment for ASD (Stalicla SFX-01 to solve this issue)
* Stalicla deal is worth £165 million
* America alone has 1.7M people with ASD (this is seen as Evgen's main market)
* Looking for similar deals to advance breast cancer research

Answers from Q+As

* The board could not buy stock during the negotiations regarding the Stalicla deal, for fear of insider trading, although they would like to buy more stock in the future
* The board have been in negotiations with Stalicla from January 2022
* A takeover was deemed to be unlikely as the product has not reached market yet
* The larger intuitional investors are in for the long hall (AXA since 2015 and Octopus since 2021)

What's not to like?

GLA.

I'm waiting on money clearing to buy more. This stock is a steal at these prices!

She's starting to rise in anticipation of the 1pm presentation.

I'm intending to hold these little gems until at least 2025.

One of the best prospects i've seen in the last 30 years.

All the ducks are lining up!

GLA.

I've just got in early and got 83 135 more shares at 5.99p.

Cheap at the price.

Can't wait to watch the presentation today at 1pm.

GLA.